As governments around the world grapple with the rapid emergence of modern nicotine products, a common regulatory challenge is becoming increasingly apparent. How can policymakers protect public health while ensuring that regulation remains proportionate to the risks different products actually present?
Brazil has become one of the latest countries to confront this question.
The National Health Surveillance Agency (ANVISA) is currently reviewing the regulatory status of nicotine pouches as part of wider discussions about emerging nicotine products. While the consultation focuses on Brazil, the questions under consideration are remarkably similar to those being debated across Europe, North America, and other regions. They concern youth protection, product safety, adult smoking, regulatory proportionality, and how governments should respond to innovation in nicotine delivery.
The outcome will have implications beyond Brazil. It offers an opportunity to reflect on what evidence-based regulation should look like in an increasingly diverse nicotine marketplace.
A Changing Nicotine Landscape
Traditional tobacco legislation was largely developed around combustible cigarettes and other products containing tobacco leaf. Modern nicotine pouches present a different regulatory challenge.
They are tobacco-free, smoke-free products that deliver nicotine orally without combustion. As a result, they do not fit neatly within many existing regulatory frameworks designed either for conventional tobacco products or for pharmaceuticals.
This has led to a wide variety of regulatory approaches around the world.
Some countries have introduced product standards, age restrictions, ingredient disclosure requirements, and manufacturing controls while maintaining regulated adult access. Others have moved toward prohibition or have sought to regulate nicotine products through pharmaceutical legislation.
Brazil’s consultation reflects this broader international debate over how emerging nicotine products should be governed.
Protecting Young People Remains Essential
One area where there is broad consensus is the importance of preventing youth nicotine uptake.
Protecting children and adolescents remains a central objective of public health policy regardless of how nicotine products are classified. Strong age-of-sale laws, responsible marketing restrictions, retail compliance measures, and enforcement mechanisms are fundamental components of any effective regulatory framework.
However, youth protection does not necessarily determine whether prohibition represents the most effective regulatory response.
Many jurisdictions have demonstrated that youth safeguards can coexist with regulated adult access through licensing systems, product standards, marketing controls, packaging requirements, and ongoing market surveillance.
The policy challenge therefore becomes identifying regulatory approaches that minimise youth access without unnecessarily limiting options for adults who already smoke.
Risk Matters in Regulatory Design
One of the central questions raised by modern nicotine products is whether regulation should distinguish between products that present different levels of risk.
Combustible cigarettes remain uniquely harmful because they involve burning tobacco and exposing users to thousands of toxic chemicals generated through combustion.
Nicotine pouches do not involve combustion, tobacco smoke, or inhalation. While they are not risk-free and contain an addictive substance, their toxicological profile differs substantially from that of combustible cigarettes.
This distinction does not automatically determine how products should be regulated.
It does, however, suggest that regulatory frameworks should carefully consider available scientific evidence regarding comparative risk when designing product standards, taxation, market access, and consumer protections.
A growing number of international reviews have argued that regulation should reflect meaningful differences in exposure to harmful constituents while continuing to recognise the need for strong safeguards.
The Importance of Product Standards
One lesson emerging from international experience is that effective regulation involves considerably more than deciding whether products should be legal or prohibited.
Robust regulatory frameworks increasingly focus on product quality and consumer protection.
These measures may include maximum nicotine concentrations, ingredient disclosure requirements, manufacturing standards, contaminant limits, packaging requirements, product notification systems, and post-market surveillance.
Such approaches allow regulators to oversee product quality while reducing uncertainty for both consumers and manufacturers.
As new nicotine categories continue to evolve, clear product standards may become one of the most important components of effective regulation.
The Risks of Regulatory Gaps
Another important consideration is the potential impact of regulatory gaps.
Experience from numerous regulated markets suggests that consumer demand rarely disappears simply because products become unavailable through legal channels.
Where legal access is severely restricted, policymakers may face increased risks associated with informal supply chains, cross-border purchasing, counterfeit products, and reduced regulatory oversight.
This does not mean that every product should remain legally available. Rather, it highlights the importance of considering how regulatory decisions influence consumer behaviour and market dynamics.
Public health policy is often most effective when it considers not only intended outcomes but also potential unintended consequences.
Learning from International Experience
Brazil is far from alone in facing these questions.
Across Europe, nicotine pouch regulation has become one of the most actively debated areas of tobacco and nicotine policy. Countries including Sweden, the Czech Republic, Switzerland, and the United Kingdom have adopted regulatory models that combine adult access with varying degrees of product oversight and youth protection. Others have pursued more restrictive approaches, reflecting different assessments of public health priorities.
These differing models demonstrate that governments are not limited to a binary choice between unrestricted availability and outright prohibition.
A range of regulatory options already exists.
Examining international experience allows policymakers to assess which approaches have been most effective in protecting young people, maintaining product standards, supporting enforcement, and responding to evolving scientific evidence.
Evidence-Based Regulation Requires Proportionality
As Brazil considers the future regulation of nicotine pouches, one principle deserves particular attention: proportionality.
Proportionate regulation does not imply deregulation. Nor does it diminish the importance of preventing youth initiation or ensuring product safety.
Instead, it recognises that regulatory measures should be guided by the best available scientific evidence, reflect meaningful differences between product categories, and remain adaptable as new evidence emerges.
This includes applying robust safeguards where risks exist while avoiding assumptions that fundamentally different products necessarily warrant identical regulatory treatment.
Evidence-based regulation is rarely about choosing between public health protection and innovation.
It is about finding regulatory approaches capable of achieving both.
Looking Ahead
Brazil’s consultation represents more than a national regulatory review. It reflects a broader global transition in nicotine governance.
As smoke-free nicotine products continue to emerge, policymakers around the world are being asked to reconsider whether existing regulatory frameworks remain fit for purpose.
The challenge is not whether nicotine products should be regulated. They should be.
The challenge is developing regulatory systems that protect young people, ensure product quality, maintain effective market oversight, and remain proportionate to the risks products are likely to present.
Brazil now has an opportunity to contribute to that global conversation.
Whatever regulatory path is ultimately chosen, the consultation reinforces an increasingly important principle: modern nicotine products require modern regulatory thinking, grounded in evidence, responsive to scientific developments, and focused on achieving the best possible public health outcomes.
Source
https://tobaccoharmreduction.net/article/nicotine-product-regulation-brazil-anvisa-expert-response/
